Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder



	Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted
	Citation Map



	Email this article to a Colleague
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Add to My Articles & Searches
	Download to citation manager



	Citing Articles via HighWire
	Citing Articles via Google Scholar



	Articles by Calabrese, J. R.
	Articles by Delucchi, G. A.
	Search for Related Content



	PubMed Citation
	Articles by Calabrese, J. R.
	Articles by Delucchi, G. A.

Am J Psychiatry 1990; 147:431-434
Copyright © 1990 by American Psychiatric Association

REGULAR ARTICLES

Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder

JR Calabrese and GA Delucchi
Department of Psychiatry, University Hospital of Cleveland, Case Western Reserve University, OH 44106.

In order to explore valproate's spectrum of efficacy in rapid-cycling bipolar disorder, 55 patients underwent a prospective, open, 7.8-month trial designed to assess the drug's acute and prophylactic properties. Twenty patients received monotherapy, and 35 received combination therapy. Moderate to marked acute antidepressant responses were seen in 47% of the patients, prophylactic antidepressant responses in 76%, acute antimanic responses in 91%, prophylactic antimanic responses in 94%, acute responses in mixed states in 85%, and prophylactic responses in mixed states in 93%. Consistent with other anticonvulsant literature, these data suggest that valproate has marked antimanic and mixed state efficacy, but minimal to moderate antidepressant properties.

This article has been cited by other articles:

J. Cookson and B. Elliott
The use of anticonvulsants in the aftermath of mania.
J Psychopharmacol, March 1, 2006; 20(2_suppl): 23 - 30.
[Abstract] [PDF]

J. R. Calabrese, M. D. Shelton, D. J. Rapport, E. A. Youngstrom, K. Jackson, S. Bilali, S. J. Ganocy, and R. L. Findling
A 20-Month, Double-Blind, Maintenance Trial of Lithium Versus Divalproex in Rapid-Cycling Bipolar Disorder
Am J Psychiatry, November 1, 2005; 162(11): 2152 - 2161.
[Abstract] [Full Text] [PDF]

K. R. R. Krishnan
Psychiatric and Medical Comorbidities of Bipolar Disorder
Psychosom Med, January 1, 2005; 67(1): 1 - 8.
[Abstract] [Full Text] [PDF]

J. M. Pellock
Understanding co-morbidities affecting children with epilepsy
Neurology, March 9, 2004; 62(90052): S17 - 23.
[Abstract] [Full Text]

D. F. MacKinnon, P. P. Zandi, E. Gershon, J. I. Nurnberger Jr, T. Reich, and J. R. DePaulo
Rapid Switching of Mood in Families With Multiple Cases of Bipolar Disorder
Arch Gen Psychiatry, September 1, 2003; 60(9): 921 - 928.
[Abstract] [Full Text] [PDF]

M. L. Gilmor, K. H. Skelton, C. B. Nemeroff, and M. J. Owens
The Effects of Chronic Treatment with the Mood Stabilizers Valproic Acid and Lithium on Corticotropin-Releasing Factor Neuronal Systems
J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 434 - 439.
[Abstract] [Full Text] [PDF]

M. H. Rapaport and D. J. Hales
Relapse Prevention and Bipolar Disorder: A Focus on Bipolar Depression
Focus, January 1, 2003; 1(1): 15 - 31.
[Abstract] [Full Text] [PDF]

R. M.A. Hirschfeld, C. L. Bowden, M. J. Gitlin, P. E. Keck, R. H. Perlis, T. Suppes, M. E. Thase, and K. D. Wagner
Practice Guideline for the Treatment of Patients With Bipolar Disorder (Revision)
Focus, January 1, 2003; 1(1): 64 - 110.
[Full Text] [PDF]

I. N. FERRIER, I. C. MacMILLAN, and A. H. YOUNG
The search for the wandering thymostat: a review of some developments in bipolar disorder research
The British Journal of Psychiatry, June 1, 2001; 178 (41): s103 - s106.
[Full Text] [PDF]

C. L. Bowden, J. R. Calabrese, S. L. McElroy, L. Gyulai, A. Wassef, F. Petty, H. G. Pope Jr, J. C.-Y. Chou, P. E. Keck Jr, L. J. Rhodes, et al.
A Randomized, Placebo-Controlled 12-Month Trial of Divalproex and Lithium in Treatment of Outpatients With Bipolar I Disorder
Arch Gen Psychiatry, May 1, 2000; 57(5): 481 - 489.
[Abstract] [Full Text] [PDF]

J. Walsh
Psychopharmacological Treatment of Bipolar Disorder
Research on Social Work Practice, July 1, 1998; 8(4): 406 - 425.
[Abstract] [PDF]

D. G. Watson, J. M. Watterson, and R. H. Lenox
Sodium Valproate Down-regulates the Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) in Immortalized Hippocampal Cells: A Property of Protein Kinase C-Mediated Mood Stabilizers
J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 307 - 316.
[Abstract] [Full Text]

Get information about faster international access.